New antithrombotic drugs: antithrombotic therapy and prevention of thrombosis: American college of chest physicians evidence-based clinical practice guidelines
JI Weitz, JW Eikelboom, MM Samama - Chest, 2012 - Elsevier
This article focuses on new antithrombotic drugs that are in or are entering phase 3 clinical
testing. Development of these new agents was prompted by the limitations of existing …
testing. Development of these new agents was prompted by the limitations of existing …
[PDF][PDF] New Antithrombotic Drugs
JI Weitz, JW Eikelboom, MM Samama - Chest, 2012 - 11871494.s21i.faiusr.com
The limitations of existing antiplatelet drugs reflect, at least in part, their capacity to attenuate
only a single pathway of platelet activation. Because platelets can be activated via multiple …
only a single pathway of platelet activation. Because platelets can be activated via multiple …
[PDF][PDF] New Antithrombotic Drugs
JI Weitz, JW Eikelboom, MM Samama - Chest, 2012 - academia.edu
The limitations of existing antiplatelet drugs reflect, at least in part, their capacity to attenuate
only a single pathway of platelet activation. Because platelets can be activated via multiple …
only a single pathway of platelet activation. Because platelets can be activated via multiple …
[PDF][PDF] New Antithrombotic Drugs
JI Weitz, JW Eikelboom, MM Samama - Chest, 2012 - cpccn.org
The limitations of existing antiplatelet drugs reflect, at least in part, their capacity to attenuate
only a single pathway of platelet activation. Because platelets can be activated via multiple …
only a single pathway of platelet activation. Because platelets can be activated via multiple …
[PDF][PDF] New Antithrombotic Drugs
JI Weitz, JW Eikelboom, MM Samama - CHEST, 2012 - Citeseer
The limitations of existing antiplatelet drugs reflect, at least in part, their capacity to attenuate
only a single pathway of platelet activation. Because platelets can be activated via multiple …
only a single pathway of platelet activation. Because platelets can be activated via multiple …
[PDF][PDF] New Antithrombotic Drugs
JI Weitz, JW Eikelboom, MM Samama - CHEST, 2012 - jvsmedicscorner.com
The limitations of existing antiplatelet drugs reflect, at least in part, their capacity to attenuate
only a single pathway of platelet activation. Because platelets can be activated via multiple …
only a single pathway of platelet activation. Because platelets can be activated via multiple …
New antithrombotic drugs: Antithrombotic Therapy and Prevention of Thrombosis: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
JI Weitz, JW Eikelboom, MM Samama - Chest, 2012 - europepmc.org
This article focuses on new antithrombotic drugs that are in or are entering phase 3 clinical
testing. Development of these new agents was prompted by the limitations of existing …
testing. Development of these new agents was prompted by the limitations of existing …
[HTML][HTML] New Antithrombotic Drugs: Antithrombotic Therapy and Prevention of Thrombosis: American College of Chest Physicians Evidence-Based Clinical Practice …
JI Weitz, JW Eikelboom, MM Samama - Chest, 2012 - ncbi.nlm.nih.gov
This article focuses on new antithrombotic drugs that are in or are entering phase 3 clinical
testing. Development of these new agents was prompted by the limitations of existing …
testing. Development of these new agents was prompted by the limitations of existing …
[PDF][PDF] New Antithrombotic Drugs
JI Weitz, JW Eikelboom, MM Samama - CHEST, 2012 - srcv.ro
The limitations of existing antiplatelet drugs reflect, at least in part, their capacity to attenuate
only a single pathway of platelet activation. Because platelets can be activated via multiple …
only a single pathway of platelet activation. Because platelets can be activated via multiple …
New Antithrombotic Drugs: Antithrombotic Therapy and Prevention of Thrombosis: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
JI Weitz, JW Eikelboom, MM Samama - CHEST, 2012 - journal.chestnet.org
This article focuses on new antithrombotic drugs that are in or are entering phase 3 clinical
testing. Development of these new agents was prompted by the limitations of existing …
testing. Development of these new agents was prompted by the limitations of existing …